Monday, October 23
Tuesday-Wednesday, October 24-25
Tuesday, October 24
Dinner SC3: Validation of ADA Assays and Cut Point Calculations
Wednesday, October 25
Dinner SC4: Putting Together an Integrated Summary of Immunogenicity
Dinner SC5: A Systems Pharmacology Approach for Immunogenicity Prediction
Dinner SC6: Strategic/Modular Bioassay Design and Analysis
Join us at the #1 Immunogenicity & Bioassay Event in the U.S. for CHI's Ninth Annual Immunogenicity and Bioassay Summit. The summit will host 250+ industry, academia and regulatory authorities who will share new ways of overcoming immunogenicity and bioassay challenges at 3 co-located conferences, 5 short courses, and 2 training seminars. Plus, a full day symposium on Bioassays for Immuno-Oncology. We extend our gratitude to all past speakers, alumni, sponsors and exhibitors for making this event happen. All speaker submitters will be notified of their status.
Viswanath Devanarayan, Ph.D.
University of Illinois at Chicago
Susan Kirshner, Ph.D.
Associate Chief, Immunology Lab, Therapeutic Proteins, Biotechnology
Thomas Little, Ph.D.
President, Bioassay Sciences
Thomas A. Little Consulting
Chief Technology Officer
Joao Pedras-Vasconcelos, Ph.D.
Biotech Quality and Immunogenicity Reviewer, Biotechnology Products
Amy S. Rosenberg, M.D.
Division Director, Office of Biotechnology Products
Senior Statistician, Non-Clinical Statistics
2016 Event Stats:
- 250+ Delegates from 145 Companies
- 60 Speakers
- 25 Posters Presented
- 15 Countries Represented
- 14 Exhibiting Companies
Here's what one of our delegate's on-site said:
"CHI's Optimizing Bioassay for Biologics is one of the best bioassay venues in the biotech and biopharma industry. The conference provides very deep and broad scientific presentations, roundtable discussions, and excellent network opportunities for scientists, managers/directors, CROs, vendors and consultants."
- Senior Group Leader, Bioassay Development, Hospira, a Pfizer Company
"Program and participants first class."
- Associate Director, Novo Nordisk
"Breakout interaction with FDA experts was very valuable."
- Associate Director, Alexion Pharmaceuticals Inc.
"Interesting new data and very relevant to the field."
- Senior Scientist, Process Development, Amgen, Inc.
"Provided good overview of current problems and progress in the field."
- Scientist, Bioanalytical Sciences, Immunogen
"Congratulations on a very well put together conference."
- Assistant Vice President, Pfizer
> View more testimonials